DT-Web

DB00034 - Interferon Alfa-2a, Recombinant


Identification
Name Interferon Alfa-2a, Recombinant
Accession Number DB00034 (BIOD00012, BIOD00095, BTD00012, BTD00095, DB00037)
Type biotech
Description Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 19241.1000
Groups approved
Monoisotopic Weight Not Available
Pharmacology
Indication For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
Mechanism of action Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Absorption Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.
Protein binding Not Available
Biotransformation Not Available
Route of elimination Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.
Toxicity Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Aminophylline Interferon increases the effect and toxicity of theophylline
Dyphylline Interferon increases the effect and toxicity of theophylline
Oxtriphylline Interferon increases the effect and toxicity of theophylline
Theophylline Interferon increases the effect and toxicity of theophylline
Food Interactions
  • Avoid alcohol.

Targets


Interferon-alpha/beta receptor alpha chain
Name Interferon-alpha/beta receptor alpha chain
Gene Name IFNAR1
Pharmacological action yes
Actions Not Available
References
  • Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. - Pubmed
  • Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. - Pubmed
DTHybrid score 1.8511
Interferon-alpha/beta receptor beta chain
Name Interferon-alpha/beta receptor beta chain
Gene Name IFNAR2
Pharmacological action yes
Actions Not Available
References
  • Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. - Pubmed
  • Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. - Pubmed
DTHybrid score 1.8511

Predictions


Id Partner name Gene Name Score
↑